27620-10-6

Usage

Uses

Used in Pharmaceutical Synthesis:
N-HYDROXYBUTYRAMIDINE is used as an intermediate in the synthesis of various pharmaceuticals and organic compounds. Its unique chemical structure allows it to be a versatile building block for the development of new drugs and therapeutic agents.
Used in Therapeutic Applications:
N-HYDROXYBUTYRAMIDINE is used as a potential therapeutic agent for the treatment of various diseases and health conditions. Its potential antioxidant and anti-inflammatory properties make it a promising candidate for further research and development in the pharmaceutical industry.
Used in Antioxidant and Anti-Inflammatory Research:
N-HYDROXYBUTYRAMIDINE is used as a target for research in the development of new antioxidants and anti-inflammatory agents. Its potential to combat oxidative stress and inflammation may lead to the discovery of novel treatments for a wide range of conditions.
Used in Drug Delivery Systems:
N-HYDROXYBUTYRAMIDINE may be used in the development of drug delivery systems to improve the bioavailability and therapeutic outcomes of various pharmaceuticals. Its solubility in water and organic solvents makes it a suitable candidate for incorporation into different drug delivery platforms.

InChI:InChI=1/C4H10N2O/c1-2-3-4(5)6-7/h7H,2-3H2,1H3,(H2,5,6)

Upstream product

• 109-74-0 propyl cyanide 

Downstream Products

• 146436-68-2 5-(3-Propyl-[1,2,4]oxadiazol-5-yl)-1-trityl-1,4,5,6-tetrahydro-pyrimidine 
• 4128-37-4 1,3-diisopropylurea 
• 1041005-75-7 N-isopropyl-3-propyl-1,2,4-oxadiazol-5-amine 
• 1037779-41-1 4-(3-(3-fluoro-4-methanesulfonylphenoxy)propyl)-1-(3-propyl-[1,2,4]oxadiazol-5-yl)piperidine 

Relevant academic research and scientific papers

Copper-catalyzed one-pot synthesis of 1,2,4-triazoles from nitriles and hydroxylamine

A simple and efficient copper-catalyzed one-pot synthesis of substituted 1,2,4-triazoles through reactions of two nitriles with hydroxylamine has been developed. The protocol uses simple and readily available nitriles and hydroxylamine hydrochloride as th

One-Pot Synthesis of N-Monosubstituted Ureas from Nitriles via Tiemann Rearrangement

Amidoximes, obtained from the reaction of nitriles with hydroxylamine, underwent Tiemann rearrangement in the presence of benzenesulfonyl chlorides (TsCl or o-NsCl) to form the N-substituted cyanamides. Subsequently, acidic hydrolysis of the cyanamides afforded the corresponding N-monosubstituted ureas. The synthesis of N-monosubstituted ureas from nitriles was accomplished by three steps in one pot, which provides a direct access to versatile N-monosubstituted urea derivatives from a wide variety of nitriles.

OXADIAZOLE COMPOUNDS

The present invention relates to a compound of formula (I) or (II) or a stereoisomer, enantiomer, racemic, or tautomer thereof, (I) (II) wherein R1,R2,R3,L1,L2,L3,L4,L5 and n, have the same meaning as that defined in the claims and the description. The present invention also relates to compositions, in particular pharmaceuticals, comprising such compounds, and to uses of such compounds and compositions for the prevention and/or treatment of metabolic disorders and/or neurodegenerative diseases, and/or protein misfolding disorders.

Synthesis and methemoglobinemia-inducing properties of benzocaine isosteres designed as humane rodenticides

A number of isosteres (oxadiazoles, thiadiazoles, tetrazoles and diazines) of benzocaine were prepared and evaluated for their capacity to induce methemoglobinemia - with a view to their possible application as humane pest control agents. It was found that an optimal lipophilicity for the formation of methemoglobin (metHb) in vitro existed within each series, with 1,2,4-oxadiazole 3 (metHb% = 61.0 ± 3.6) and 1,3,4-oxadiazole 10 (metHb% = 52.4 ± 0.9) demonstrating the greatest activity. Of the 5 candidates (compounds 3, 10, 11, 13 and 23) evaluated in vivo, failure to induce a lethal end-point at doses of 120 mg/kg was observed in all cases. Inadequate metabolic stability, particularly towards hepatic enzymes such as the CYPs, was postulated as one reason for their failure.

Practical synthesis of N -substituted cyanamides via tiemann rearrangement of amidoximes

A facile and general synthesis of various N-substituted cyanamides was accomplished by the Tiemann rearrangement of amidoximes with benzenesulfonyl chlorides (TsCl or o-NsCl) and DIPEA.

Synthesis of amidoximes using an efficient and rapid ultrasound method

This is a report on an efficient and rapid synthesis of amidoximes using ultrasound irradiation with appropriate nitrile and hydroxylamine hydrochloride in water/ethanol. This new synthetic methodology is compared with previously known methods. The main a

Discovery of the first potent and orally efficacious agonist of the orphan G-protein coupled receptor 119

GPR119 is a rhodopsin-like GPCR expressed in pancreatic β-cells and incretin releasing cells in the GI tract. As with incretins, GPR119 increases cAMP levels in these cell types, thus making it a highly attractive potential target for the treatment of dia

HETEROCYCLIC DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): where x, y, G, J, K, L, M, V R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.

ORGANIC COMPOUNDS

Compounds of Formula (I); in free or salt form, wherein Ra, Rb, R2, R3, R4 and R5 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by mediated by phosphatidylinositol 3-kinase. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.